It would therefore be imperative to assess the potential of targeting S-nitrosylated GAPDH for proteolysis as a therapeutic approach for alleviating tauopathy memory loss, AD, or other tau-related NDDs. The gene discussed is MAPT; the disease is Alzheimer disease.